ArticleMicrobiology spectrum2025
SCovid v2.0: a comprehensive resource to decipher the molecular characteristics across tissues in COVID-19 and other human coronaviruses.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Purification and Identification of Antimicrobial Peptides Produced by Thermophilic Bacteria Isolated from Hot Springs.Probiotics and antimicrobial proteins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
SCovid v2.0 (http://bio-annotation.cn/scovid or http://bio-computing.hrbmu.edu.cn/scovid/) is an updated database designed to assist researchers in uncovering the molecular characteristics of coronavirus disease 2019 (COVID-19) across various tissues through transcriptome sequencing. Compared with its predecessor, SCovid v2.0 is enhanced with comprehensive data, practical functionalities, and a reconstructed pipeline. The current release includes (i) 3,544,360 cells from 45 single-cell RNA-seq (scRNA-seq) data sets encompassing 789 samples from 15 tissues; (ii) the addition of 62 COVID-19 bulk RNA-seq data comprising 1,688 samples from 12 tissues; (iii) incorporation of seven bulk RNA-seq data sets related to other human coronaviruses, such as HCoV-229E, HCoV-OC43, and MERS-CoV for a thorough comparative analysis of pan-coronavirus mechanisms in COVID-19; and (iv) systematic comparisons between the data sets conducted using standardized procedures. Furthermore, we have developed an advanced search engine and upgraded web interface to browse, search, visualize, and download detailed information. Overall, SCovid v2.0 is a valuable resource for exploring molecular characteristics of COVID-19 across different tissues. IMPORTANCE: This manuscript provides a comprehensive analysis of the molecular characteristics of COVID-19 through cross-tissue transcriptome analysis, contributing to the understanding of COVID-19 by clinicians and scientists. Considering the cyclical nature of coronavirus outbreaks, this updated database adds transcriptome data on other human coronaviruses, contributing to potential and existing mechanisms of other human coronaviruses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.